Biotech Values

[miljenko]

I am not putting two compm against each other, comparing two platform that will shape future of the CoV2. Two technology platform:
mRNA.... unproven but sound, and
Adenovirus vector...MERS and SARS demonstrate limited ability.

Am I blind, as I do not see much difference in Oxford vaccine preliminary data (immunology) relative to Moderna vaccine? Actually, lower nAbs titer! And than this,

However, a boost in cellular responses was not
observed following the second ChAdOx1 nCoV-19 dose.
This is consistent with previous findings on viral vectored
vaccines given as part of a homologous prime-boost
regimen.12

make it useless for any sequential vaccination?
I think (and IMO), Pfizer/BioNT have so far best preliminary data.